Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shannon W Finks

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
The Annals of Pharmacotherapy|February 2, 2006
Bivalirudin use in carotid endarterectomy in a patient with heparin-induced thrombocytopeniaShannon W Finks
Southern Medical Journal|June 27, 2008
Re-examining the cardiovascular therapeutic benefits of aspirinShannon W Finks
The American Journal of Medicine|April 10, 2017
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?Caitlin M Gibson, Shannon W Finks
The Nurse Practitioner|October 18, 2014
Avoiding patient morbidity: Updated statin drug interactions and risks for patient harmShannon W Finks, Jennifer D Campbell
The American Journal of Medicine|December 25, 2016
Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral AnticoagulantShannon W Finks, Kelly C Rogers
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 27, 2007
Job-sharing. Drs. Finks and Rogers interviewed by Kate Traynor, M.S., AJHP News writerShannon W Finks, Kelly C Rogers
The American Journal of Medicine|July 28, 2018
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA)Kelly C Rogers, Shannon W Finks
American Journal of Pharmaceutical Education|December 5, 2009
Job sharing for women pharmacists in academiaKelly C Rogers, Shannon W Finks
Cardiovascular Diagnosis and Therapy|July 28, 2017
Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary interventionRahman Shah, Glenda Delgado, Shannon W Finks
Pharmacotherapy|July 29, 2008
Aspirin resistance: disparities and clinical implicationsAnita Airee, Heather M Draper, Shannon W Finks
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
The Annals of Pharmacotherapy|February 2, 2006
Bivalirudin use in carotid endarterectomy in a patient with heparin-induced thrombocytopeniaShannon W Finks
Southern Medical Journal|June 27, 2008
Re-examining the cardiovascular therapeutic benefits of aspirinShannon W Finks
The American Journal of Medicine|April 10, 2017
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?Caitlin M Gibson, Shannon W Finks
The Nurse Practitioner|October 18, 2014
Avoiding patient morbidity: Updated statin drug interactions and risks for patient harmShannon W Finks, Jennifer D Campbell
The American Journal of Medicine|December 25, 2016
Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral AnticoagulantShannon W Finks, Kelly C Rogers
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 27, 2007
Job-sharing. Drs. Finks and Rogers interviewed by Kate Traynor, M.S., AJHP News writerShannon W Finks, Kelly C Rogers
The American Journal of Medicine|July 28, 2018
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA)Kelly C Rogers, Shannon W Finks
American Journal of Pharmaceutical Education|December 5, 2009
Job sharing for women pharmacists in academiaKelly C Rogers, Shannon W Finks
Cardiovascular Diagnosis and Therapy|July 28, 2017
Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary interventionRahman Shah, Glenda Delgado, Shannon W Finks
Pharmacotherapy|July 29, 2008
Aspirin resistance: disparities and clinical implicationsAnita Airee, Heather M Draper, Shannon W Finks
Pageof 5